Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Rati Pinhe, Joyce Zhou, and Priyanka Grover.
Our next presenting company is Ultragenyx. And presenting on behalf of the company, we have CEO, Emil Kakkis. Emil?
Thank you, Anupam. I'm certainly happy to be here at the JPMorgan conference again to give you an update on Ultragenyx.
This is our forward-looking statement. We're a company that's leading the future of rare disease medicine. That means the company works on first-ever treatments and diseases have never seen a treatment forward, developing new ways of measuring, studying, and developing drugs for these treatments. And we try to help not only ourselves, but other companies as well as patient foundations, and it seems like everyone is doing rare-disease drug development these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
